Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Inclusion Criteria

• •1. Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or gliosarcoma;
• •2. Measurable disease by RANO criteria;
• •3. Disease progression or recurrence following standard of care treatment with temozolomide and radiation;
• •4. An interval of at least 4 weeks between prior surgical resection and study enrollment;
• •5. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from prior chemotherapy, and enrollment in this protocol;
• •6. Recovered to Grade 1 or less from the toxic effects of any earlier intervention;
• •7. Karnofsky performance status \> 60%